Author: [email protected]

Big Pharma’s Patent Cliff Could Spark a New Wave of Small-Cap Biotech Acquisitions

Posted on by [email protected]

As major pharmaceutical companies face billions in potential revenue losses from expiring patents, smaller biotechnology firms could become increasingly attractive acquisition targets.

The biotechnology sector could be approaching another wave of merger and acquisition activity as major pharmaceutical companies confront a growing challenge: the expiration of patent protection on blockbuster medications. With an estimated $300 billion to $400 billion in pharmaceutical revenue facing patent-related pressure beginning in 2028, large drugmakers are increasingly focused on replenishing their development pipelines, potentially creating opportunities for smaller biotechnology companies.

The industry’s so-called “patent cliff” occurs when branded medications lose market exclusivity, allowing generic or biosimilar competitors to enter the market. These alternatives can rapidly erode sales, forcing pharmaceutical manufacturers to identify new sources of revenue.

For small-cap biotechnology investors, this dynamic could become an important catalyst for dealmaking.

Pharmaceutical companies have several options for replacing revenue from aging products, including internal research, licensing agreements, strategic partnerships, and acquisitions. Purchasing smaller biotechnology companies with promising clinical assets can provide access to new treatments without starting development programs from scratch.

Merger and acquisition activity across the pharmaceutical and life sciences sectors continues to reflect growing demand for innovative treatments and promising drug development pipelines. Oncology, immunology, rare diseases, and other specialized therapeutic areas remain key areas of strategic interest as major pharmaceutical companies seek new opportunities for long-term growth.

Among emerging biotechnology companies advancing treatments in these fields is Cardiff Oncology (NASDAQ: CRDF), which is developing onvansertib, a PLK1 inhibitor being studied in combination with standard therapies for metastatic colorectal cancer. The company reported encouraging Phase 2 results and has outlined plans for a registrational trial, subject to additional financing.

Such programs illustrate the type of clinical innovation occurring across the smaller biotechnology sector.

Biotechnology companies frequently operate without commercial revenue, relying on capital markets to finance expensive clinical trials and regulatory development.

This funding environment can make partnerships particularly valuable.

Ocugen (NASDAQ: OCGN), which is developing gene therapies targeting inherited retinal diseases, has pursued regional licensing opportunities as part of its broader development strategy. Such arrangements demonstrate how smaller biotechnology companies can access additional resources while retaining certain commercial rights.

Meanwhile, Eledon Pharmaceuticals (NASDAQ: ELDN) is developing therapies involving immune modulation, including tegoprubart, an investigational treatment being studied in kidney transplantation.

These companies represent different approaches to addressing significant medical needs, highlighting the range of assets that larger pharmaceutical companies may evaluate when expanding their portfolios.

Their inclusion does not imply that acquisition discussions are underway.

Although pharmaceutical patent expirations create incentives for acquisitions, clinical progress remains central to company valuations.

Investors should monitor trial results, regulatory milestones, cash reserves, intellectual property protection, and licensing announcements. Companies approaching pivotal clinical milestones may attract greater strategic attention, but they also face substantial development risks.

Another consideration is whether pharmaceutical buyers favor outright acquisitions or licensing agreements that provide access to promising treatments without assuming full development costs.

Following a slowdown in biotechnology dealmaking over the summer, industry observers anticipate renewed acquisition interest as companies prepare for upcoming patent expirations.

For investors following the small-cap biotechnology sector, the implications extend beyond potential takeover premiums. Increased dealmaking could improve sentiment, provide additional financing opportunities, and establish valuation benchmarks for emerging therapeutic platforms.

As the pharmaceutical industry prepares for significant revenue losses from patent expirations, innovative smaller biotechnology companies could play an increasingly important role in shaping the next generation of treatments.

Critical Minerals Race Fuels Mining Deals as Companies Move to Secure Copper and Rare Earth Supplies

Posted on by [email protected]

The global race to secure critical minerals is driving renewed merger and acquisition activity across the mining industry, as companies seek greater control over copper, rare earth elements, and other strategically important resources. Growing demand from electrification, artificial intelligence infrastructure, and defense manufacturing is encouraging producers to pursue acquisitions, strategic partnerships, and long-term supply agreements.

For small-cap and microcap mining companies, these developments could create opportunities to attract investment, advance exploration projects, and establish relationships with larger industry participants.

Recent transactions involving copper exploration assets and rare earth supply agreements highlight the increasing importance of securing access to future mineral production.

Copper remains central to global electrification, with applications spanning electric vehicles, renewable energy systems, power transmission networks, and data centers.

As electricity demand increases, mining companies are looking to expand their resource portfolios. However, developing new copper mines can require substantial investment and years of exploration, permitting, and construction.

Acquiring existing exploration assets or partnering with junior miners can offer established producers an alternative route to securing future supplies.

Kodiak Copper (KDKCF) provides an example of activity within the junior copper sector. The company is advancing its MPD copper-gold project in British Columbia, where its 2026 exploration program includes drilling intended to expand existing mineral resources and evaluate additional targets.

Kodiak has also pursued a proposed transaction involving its Mohave copper project in Arizona and assets contributed by Teck Resources, illustrating how junior miners can participate in broader asset consolidation strategies.

Another company operating in the sector is Power Metallic Mines (PNPNF), which is advancing polymetallic exploration projects in Quebec with exposure to copper and other metals important to industrial supply chains.

Beyond copper, rare earth elements have become increasingly important because of their use in electric motors, wind turbines, and advanced defense technologies.

Recent activity involving Arafura Rare Earths and commodity trader Traxys underscores the importance of long-term offtake agreements in securing future supplies.

These arrangements can provide mining developers with commercial visibility while helping industrial customers reduce exposure to concentrated global supply chains.

The broader critical minerals landscape also includes materials used in batteries and energy storage.

First Phosphate (PHOS) is focused on phosphate resources in Quebec, a material relevant to lithium iron phosphate battery chemistry. Meanwhile, Century Lithium (CYDVF) is developing its Angel Island lithium project in Nevada, positioning it within the North American battery materials supply chain.

Although these companies operate in different commodity markets, their projects illustrate the range of resources attracting strategic interest as governments and manufacturers prioritize domestic and diversified supply networks.

For junior mining investors, increasing acquisition activity could provide additional opportunities for companies with attractive deposits, favorable jurisdictions, and credible development plans.

However, stronger demand for critical minerals does not automatically translate into profitable projects.

Investors should evaluate resource quality, project economics, financing requirements, permitting risks, and potential shareholder dilution.

Strategic equity investments, joint ventures, government funding commitments, and binding offtake agreements may offer important indications of commercial interest.

As competition for critical minerals intensifies, securing reliable access to future production is becoming an increasingly important priority.

For small-cap mining companies, this environment could support additional partnerships and consolidation activity, making critical minerals a sector worth watching through the remainder of 2026 and beyond.

The $4 Gallon Is No Longer a Shock. It’s the New Baseline.

Posted on by [email protected]

By Wednesday, American drivers are expected to log more days above $4 a gallon in a single year than in any year on record, surpassing a mark set in 2022. That is the forecast of Patrick De Haan, head of petroleum analysis at GasBuddy, and the numbers support it.

AAA puts the national average for regular gasoline at $4.35 a gallon, about $1.27 higher than a year ago and still shy of the May peak above $4.50. Diesel sits at $6.25. Prices have drifted down a few cents over the past month, which is hardly comfort when the starting point is this high.

What stands out is not the peak but the persistence. A price spike is a shock; a price that stays elevated for months becomes a baseline. Households stop treating $4 gas as an emergency and start budgeting around it, which means cutting somewhere else. That quiet adjustment is how fuel costs feed into broader economic weakness, and it helps explain why consumers have grown so frustrated with the cost of living. The University of Michigan’s October sentiment survey fell to a five-month low, and gas prices that have held above $4 since mid-summer are part of that story.

The supply picture offers little relief. Crude rose Monday after deadly attacks in the Middle East and fresh doubts about a proposed Russia-Ukraine energy ceasefire, with Brent near $106 a barrel and West Texas Intermediate around $93. At home, Hurricane Isaias knocked two major Gulf Coast refineries offline, and the full extent of the damage is still being assessed. Refiners make diesel and heating oil from the same crude supply, so a disruption in one product can pull the others higher, just as winter demand arrives. Gasoline futures are up more than 86% this year and heating oil futures more than 124%.

Diesel deserves more attention than it gets. It moves the farm equipment, trucks, and delivery vans that carry nearly everything people buy, so higher diesel costs eventually show up on shelves and invoices. Drivers see the gasoline price on a sign; they don’t see the diesel surcharge folded into their groceries.

The pain is not evenly shared. Producers are positioned to benefit. InPlay Oil Corp. (IPOOF), an Alberta light oil producer covered by Noble Capital Markets research, reported record quarterly adjusted funds flow of $44.7 million in the second quarter, citing high oil prices, and raised its 2026 guidance. The company also reported production of 18,663 barrels of oil equivalent per day, about 62% light oil and natural gas liquids, and agreed to a $54.25 million acquisition after quarter end. Those figures are company-reported. Transportation and logistics businesses, along with lower-income households that spend a larger share of their budgets on fuel, face the opposite side of the trade.

Three things will decide how long this lasts: how quickly the damaged refineries come back, whether Middle East tensions and the Russia-Ukraine ceasefire push crude higher, and how tight distillate supply gets as temperatures fall. If those break the wrong way, the $4 gallon will remain a feature of the economy rather than a talking point, and the consumer will keep feeling it.

IonQ to Acquire Zero Trust Security Firm Elisity in Deal Valued at Up to $1.3 Billion

Posted on by [email protected]

IonQ (NYSE: IONQ) announced on Oct. 12 that it has agreed to acquire Elisity, a Zero Trust cybersecurity company, in an all-stock transaction valued at up to $1.3 billion. The deal pairs IonQ’s post-quantum cryptography (PQC) and quantum key distribution (QKD) technology with Elisity’s enterprise network security platform, and it extends IonQ’s push beyond quantum computing into security.

Founded in 2019, Elisity helps organizations apply Zero Trust principles to users, devices, workloads, AI agents, and other non-human identities. Its IdentityGraph product pulls together identity, asset, and risk data to set least-privilege access policies, letting teams simulate a policy before enforcing it and restrict each identity to only the communications it needs. IonQ says Elisity has more than 100 customer deployments, including a growing number of Fortune 500 companies, and has roughly doubled both revenue and customers year over year with no churn among deployed customers. IonQ also points to the microsegmentation market, which it sizes at more than $10 billion with double-digit annual growth.

IonQ is pitching a single security stack for two problems: attacks happening now, including those involving AI agents, and the longer-term risk that quantum computers eventually break today’s encryption. The companies plan to extend IdentityGraph with cryptographic inventory and risk information. IonQ CEO Niccolo de Masi said “Q-Day” is arriving faster than predicted, and compared the deal to IonQ’s earlier SkyWater Technology acquisition, which added chip design and fabrication capabilities. The announcement also cites a June 22, 2026 White House executive order and other federal directives pushing agencies toward PQC migration.

IonQ says its quantum-safe communications networks are already deployed in Switzerland, Poland, Romania, and Slovakia, and that multiproduct revenue grew 40% year over year in the second quarter of 2026. Elisity’s customer base and CISO relationships would give IonQ new channels to sell PQC, QKD, and quantum computing to enterprise and government buyers.

The transaction includes up to $150 million in earnout payments tied to Elisity’s performance. The number of IonQ shares issued will be set at closing using the 20-day volume-weighted average price before closing, with the price floored at $33.07 and capped at $49.61 per share. The deal is expected to close in the fourth quarter of 2026, subject to customary conditions including regulatory approval. Elisity will continue operating under its current leadership, including CEO James Winebrenner.

Closing risk, customer and employee retention, and integration are the main variables, all flagged in IonQ’s own forward-looking statements. Investors should also watch whether IonQ can turn the cross-sell story into reported revenue, and how the share issuance affects dilution given the price collar.

Consumer Sentiment Slides to a Five-Month Low as Cost-of-Living Frustration Builds

Posted on by [email protected]

American households are growing more pessimistic about the economy. The University of Michigan’s preliminary October consumer sentiment index fell to 46.3, down from 48.1 in September and below the 47.3 reading economists had expected. It marks the weakest level in five months and underscores how persistently high prices are shaping the mood of the American consumer.

Cost of living is the common thread

Survey director Joanne Hsu said frustration over the cost of living keeps building, and that consumers across the political spectrum believe the economy has lost ground since the start of the year. With midterm elections 25 days away, sentiment improved among both Democrats and Republicans, but a decline among independents more than offset those gains.

The pain is uneven. Lower-income households and those with smaller stock portfolios, the groups with the least cushion against rising prices, saw sentiment decline this month. That divide matters: a market rally does little for the families that don’t own much of the market.

Inflation expectations are moving the wrong way

Consumers now expect prices to rise 4.7% over the next year, up from 4.6% in September and well above the 3.4% recorded in February, when the Middle East conflict and the resulting energy shock began. Long-run expectations ticked up to 3.5% from 3.4%, and they have stayed above the 2.8%–3.2% range seen in 2024. Expectations matter because they can become self-reinforcing, influencing wage demands and pricing decisions.

Energy is a major driver. Gas prices are up more than $1.50 a gallon on average since the war began, according to AAA, and have held above $4 since mid-summer.

Borrowing costs add pressure

Rates are compounding the problem. The 10-year Treasury yield has climbed above 5%, with some analysts warning it could approach 6%, a level not seen since 2000. That flows directly into household borrowing: Freddie Mac reports the average 30-year fixed mortgage rate rose to 7.4% this week, a three-year high. Concerns about a national debt now above $40 trillion are also weighing on consumer views of buying conditions.

Why it matters for investors

Consumer spending drives roughly two-thirds of U.S. economic activity, so sentiment readings are worth watching. A weak mood combined with elevated inflation expectations leaves the Federal Reserve in a difficult spot: easing is harder to justify when households expect higher prices, but tighter financial conditions risk squeezing the consumer further. Retail, housing-related, and consumer discretionary names are the most exposed if sentiment keeps deteriorating and spending follows.

What to watch next

The October figure is preliminary, and the final reading is due later this month. Investors should watch whether sentiment stabilizes or keeps sliding, whether year-ahead inflation expectations push further above 4.7%, and how the 10-year yield behaves as it flirts with higher levels. Gas prices and mortgage rates will also be telling: if they ease, the pressure on households could lift; if they keep climbing, the sentiment gap between higher- and lower-income consumers may widen further.

Xcel Brands (XELB) – Performance-Based Partnership Could Accelerate Royalty Growth

Posted on by [email protected]


Friday, October 09, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

An important evolution of the creator-commerce model. Xcel Brands announced a partnership with Paradium.AI to launch PetHelpful x Trust·Respect·Love by Cesar Millan, combining Parade’s extensive digital publishing network with Cesar Millan’s global recognition and authentic content. We believe the collaboration marks an important evolution in Xcel’s strategy, leveraging AI-powered content to convert strong consumer awareness into retail sales.

A compelling performance-based marketing model. Paradium.AI commits significant marketing resources through its media platforms to participating retailers at no cost, while Paradium.AI, Cesar Millan, and Xcel share performance-based royalties. We believe this creates an attractive proposition for retailers by providing substantial promotional support while aligning all parties’ interests around generating sales.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Resources Connection (RGP) – Pricing Holds as the Recovery Remains Elusive

Posted on by [email protected]


Friday, October 09, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Resources Connection’s first-quarter results were within management’s revenue and gross margin outlook, while lower operating expenses helped profitability exceed our July projections. However, the Company has yet to demonstrate sustained revenue improvement. We believe pricing discipline and ongoing cost actions provide a foundation for recovery, but weak consultant utilization and recent cash consumption leave less room for an extended turnaround.

1Q27 Results. Revenue was $98.1 million compared to $120.2 million in 1Q26 and our $100 million estimate. Adjusted EBITDA was a loss of $3.6 million compared to $3.1 million in 1Q26 and our projected $5.5 million loss. Adjusted net loss was $0.16/sh. versus EPS of $0.03 in 1Q26 and our $0.22/sh. loss estimate. The earnings improvement relative to our forecast is encouraging, although it does not change the need for higher billable activity.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Coal Operations Anchor Cash Flow as Oil and Gas Royalties Expand

Posted on by [email protected]


Friday, October 09, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Coal fundamentals support a constructive outlook. Alliance Resource Partners is the second-largest coal producer in the eastern United States and benefits from a competitive cost structure and strong earnings visibility based on contracted sales. More than 99% of expected 2026 coal volumes are committed and priced, while approximately 85% of anticipated 2027 volumes are contracted. Growing electricity demand and a more supportive regulatory environment could extend coal-fired power plant lives and strengthen demand for thermal coal.

Royalties strengthen the growth profile. Alliance continues to expand its high-margin oil and gas royalty business, supported by more than $1 billion invested in mineral interests. The recent $206.2 million AllDale acquisition expanded its portfolio to approximately 115,680 net royalty acres, including more than 44,770 acres in the Permian Basin. We expect royalties to contribute increasingly to earnings and cash flow without the capital requirements of operated properties.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FCC Clears SpaceX to Launch 15,000 Direct-to-Phone Satellites, Putting Wireless Carriers on Notice

Posted on by [email protected]

The FCC approved SpaceX on Wednesday, Oct. 7, to launch and operate up to 15,000 next-generation Starlink Mobile satellites that connect directly to ordinary smartphones. SpaceX has about 650 mobile satellites in orbit today. Elon Musk said on X that the new V2 constellation will deliver more than 100 times the bandwidth of the current system.

The company says the upgraded network will deliver 5G speeds of up to 150 Mbps per user, using spectrum from T-Mobile and airwaves SpaceX purchased from EchoStar. That goes beyond patching dead zones: it is a bid to offer real mobile broadband from space.

Existing rules assumed satellite operators would lease spectrum from a terrestrial carrier, which made carriers the gatekeepers. Because SpaceX now owns roughly 65 MHz of spectrum, acquired from EchoStar in two deals totaling about $19.6 billion, the FCC waived the leasing requirement, citing competition in retail wireless service. In practice, SpaceX can sell phone service without a carrier’s sign-off, which weakens the leverage of T-Mobile, its current direct-to-cell partner. SpaceX President Gwynne Shotwell added that the spectrum has terrestrial components and the company intends to build out on the ground as well.

The timeline is long. Launches are slated to begin in late 2027, and SpaceX cannot use the EchoStar spectrum commercially until the remaining part of that deal closes, expected by Nov. 30, 2027. Half the constellation must be in orbit by Oct. 7, 2032, and the full network by Oct. 7, 2035.

Capacity is also a question. Moving from about 650 to 15,000 satellites is roughly a 23-fold increase, so a 100x bandwidth gain implies each satellite carries about four times today’s load. But 150 Mbps is a peak figure, and satellite beams share capacity across wide areas. How the network performs under heavy demand in dense cities remains unproven. That points to rural and roaming customers as the first to feel competitive pressure.

AT&T, Verizon, and T-Mobile formed a satellite-to-phone joint venture on Oct. 2, but it still needs another company’s satellites. Verizon’s and AT&T’s current satellite arrangements rely on AST SpaceMobile, whose network is not yet built. AST shares fell about 4% on the news. AT&T may be the most exposed: revenue was $126 billion in fiscal 2025, down from $134 billion in 2021, so even modest rural losses would show.

The approval came from an FCC bureau rather than the full commission, so it could be reviewed. On Oct. 29, the FCC votes on auctioning 25 MHz of spectrum for direct-to-device service, and a carrier win there would narrow SpaceX’s lead. Investors should also watch whether launches begin on schedule in late 2027. Analysts project SpaceX revenue rising from $45.1 billion in fiscal 2026 to $200 billion in fiscal 2028.

Viatris to Acquire Pacira BioSciences for $1.65 Billion, Expanding Into Non-Opioid Pain Therapies

Posted on by [email protected]

Viatris (Nasdaq: VTRS) announced Thursday it has agreed to acquire Pacira BioSciences (Nasdaq: PCRX) for $36.50 per share in cash, an aggregate equity value of $1.65 billion. The deal gives Viatris two marketed, patent-protected non-opioid pain medicines and positions the company as a leader in a category where patients and physicians continue to look for alternatives to opioids.

Pacira’s portfolio rests on EXPAREL, a long-acting local anesthetic used to manage pain after surgery, and ZILRETTA, an extended-release injection for osteoarthritis knee pain. Company materials cite up to a 78% decrease in opioid consumption with EXPAREL, though the release notes the clinical benefit of that reduction was not demonstrated. Over the twelve months ended June 30, 2026, Pacira generated about $746 million in revenue and $177 million in adjusted EBITDA. On equity value alone, the price works out to roughly 2.2 times revenue and 9.3 times adjusted EBITDA. GAAP net income over the same period was a much smaller $14.6 million, reflecting significant amortization of acquired intangibles and stock-based compensation.

Viatris says the acquisition advances its push to build an innovative medicines business, and that the products complement its fast-acting meloxicam opportunity in pain. The company also gains Pacira’s U.S. commercial, market access, medical affairs, and research capabilities, along with a pipeline led by a Phase 2 gene therapy candidate for knee osteoarthritis. Viatris plans to apply its expertise in intellectual property and product lifecycle management to extend the portfolio’s reach, including across select international markets where it already operates.

Viatris expects to fund the deal primarily from excess cash, with the remainder from short-term borrowings, and says the impact on its gross leverage ratio will be minimal. The transaction is expected to be immediately accretive to its financial guidance metrics. It will be structured as a tender offer followed by a second-step merger at the same price, with both boards having unanimously approved and Pacira’s board recommending that shareholders tender. Closing requires that a majority of Pacira’s outstanding shares be tendered and that the regulatory waiting period expire, and is expected by the end of 2026. Once complete, Pacira will be delisted from Nasdaq. Viatris will discuss the transaction when it reports third-quarter results on November 5.

Pacira’s leadership said the company has helped nearly 20 million patients access non-opioid pain management and that Viatris’ scale and resources will help bring its therapies to more patients.

The thesis behind the deal is worth examining. Viatris highlighted its record of sustaining sales after competition arrives, a reminder that protected products do not stay protected forever and that part of what Viatris is paying for is its ability to manage that transition.

For small and microcap investors, the takeaway is that commercial-stage healthcare companies with profitable, differentiated products are drawing strategic interest at disciplined valuations. Roughly nine times adjusted EBITDA on equity value is a useful benchmark for smaller specialty pharma and medical technology companies with established revenue, and it reinforces a theme running through this year’s healthcare deal activity, including Supernus’s merger with Indivior and MiMedx’s acquisition of Sanara MedTech. Companies still in development are a different proposition, since their deal values depend far more on clinical milestones than on current earnings.

Take a moment to take a look at more emerging growth biotech companies by looking at Noble’s Research Analyst Robert LeBoyer’s coverage list.

Mortgage Rates Hit 7.4%, the Highest in Nearly Three Years

Posted on by [email protected]

The average 30-year fixed mortgage rate reached 7.4% this week, according to Freddie Mac survey data through Wednesday, up from 7.28% a week earlier and the highest level in nearly three years. Other measures are higher still. Mortgage News Daily calculated 7.59% as of Wednesday, the Mortgage Bankers Association reported a 7.49% average for the week through Friday, and Zillow data showed a 7.52% rate on a 30-year purchase loan today.

The climb has been steady. Freddie Mac’s 30-year average was 6.65% in late August, which means borrowing costs have risen by roughly three-quarters of a percentage point in about seven weeks. The average crossed 7% in late September for the first time in nearly three years and has kept climbing. On a $400,000 loan, a 7.4% rate means principal and interest of roughly $2,770 a month, about $290 more than at the 6.3% level of a year ago.

Mortgage rates are following bond yields higher as investors worry about government spending, inflation tied to the Iran war, and ongoing economic growth. The 10-year Treasury yield has hovered around 5.3% this week, retreating slightly after briefly touching its highest level since 2002. That link to long-term yields explains why mortgage rates have kept rising even as expectations for another Fed hike in October have faded, since home loan costs track the bond market more closely than the Fed’s policy rate.

The housing market is showing the strain. One housing economist said the higher rates have unsettled the market, noting that pending home sales fell from a year earlier in both August and September, before rates even crossed 7%, and that sellers are cutting prices at a pace not seen in four years. Higher rates reduce what buyers can afford, which pushes sellers to lower prices to attract them, and it keeps many existing homeowners with lower-rate loans from listing at all.

Refinancing is not offering much of an escape either. Zillow data put the average 30-year refinance rate at 7.41% today and the 15-year at 6.76%, while 15-year purchase loans averaged 6.70%. For buyers weighing alternatives, a 5/1 adjustable-rate mortgage averaged 7.13%, only modestly below the 30-year fixed, which limits the appeal of taking on adjustable-rate risk.

Several upcoming data points will show whether rates are close to a peak: next week’s Freddie Mac survey, the September inflation report, and the Fed’s October 27 and 28 meeting, where futures see only a small chance of another hike.

For small and microcap investors, the mortgage market is a useful read on how long-term rates are feeding into the real economy. Housing-linked businesses, from builders and building products suppliers to real estate services and home improvement retailers, are typically among the first to feel higher borrowing costs, and smaller companies with less pricing power and more floating-rate debt feel it more acutely. Mortgage-related financial companies face the same pressure through lower loan volumes. Because long yields, not the Fed, are driving this move, relief is likely to depend on easing concerns about deficits and inflation rather than on the central bank pausing.

MAIA Biotechnology (MAIA) – Patient Enrollment Completed In THIO-101, Enrollment Milestone Reached In THIO-104

Posted on by [email protected]


Thursday, October 08, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

MAIA Reported Two Important Clinical Trial Milestones. MAIA announced the completion of enrollment for the Part C Expansion Stage of the THIO-101 trial. This part of THIO-101 has enrolled 150 patients. Separately, the Phase 3 THIO-104 trial reached enrollment of 65 patients, putting it on schedule to enroll 100 patients by YE2026. Reaching the full-year enrollment goal could allow an interim analysis in FY2027.

Results From THIO-101 Part C Have Been Positive To Date. As discussed in our Research Note on September 22, MAIA recently announced initial efficacy data from the THIO-101 Part C. The evaluable population, consisting of patients with at least one post-treatment evaluation by tumor scan, showed a disease control rate (DCR) of 90.5%. This far exceeds published studies that show a 25%–35% DCR for standard third-line chemotherapy regimens.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Fed Was Unanimous on the September Hike, but October Odds Have Faded

Posted on by [email protected]

Minutes from the Federal Reserve’s September 16 meeting, released Wednesday, show that every participant agreed interest rates needed to move higher. The committee voted unanimously to raise the federal funds rate, its first increase in three years, and most members projected at least one more quarter-point hike before the end of the year.

The minutes describe a committee that saw inflation as elevated and the labor market as near full employment, with some signs of strengthening. Economic activity was expanding at a solid pace. Almost all participants judged that risks to inflation were tilted to the upside, while risks to the labor market had diminished and were now broadly balanced. That balance of risks was the basis for the hike.

But the data since that meeting has shifted the picture. Core PCE inflation, the Fed’s preferred gauge, rose 3% in August, below the 3.3% economists expected and down from 3.3% in July. Then the September jobs report came in far weaker than forecast, with just 29,000 jobs added and the unemployment rate edging up to 4.2% from 4.1%. In other words, the two conditions that justified the hike, stubborn inflation and a firming labor market, both looked softer within weeks.

Several officials had already begun tempering expectations before the jobs report. Vice Chair Philip Jefferson and New York Fed President John Williams both acknowledged that inflation remains too high but said the central bank should take time to assess whether it is on a downward path. Williams said there is no need for urgency after the September increase and that the Fed has time to gather more information. That marks a notable shift from late September, when other officials were publicly arguing that more hikes were needed. Core inflation at 3% is still well above the Fed’s 2% target, so the debate now appears to be about timing rather than direction.

Markets have adjusted accordingly. The Fed meets again October 27 and 28, and futures now price only about a 17% chance of a hike at that meeting, down from roughly two-thirds in late September. The odds of a hike in December sit near 70%, which suggests traders see the Fed pausing rather than finishing.

A pause would not necessarily bring relief to long-term borrowing costs. The 10-year Treasury yield is still near 5.3%, and much of the recent rise has reflected investors demanding higher real returns to hold long-dated debt rather than the Fed’s policy rate, a dynamic that a pause in hikes may do little to change.

For small and microcap investors, the shift matters. Roughly 32% of Russell 2000 companies carry floating-rate debt, compared with about 6% of S&P 500 companies, so changes in the expected path of short-term rates flow more directly into smaller companies’ interest costs. A pause at the current range of 3.75% to 4.00% would stabilize that expense, while a December hike would extend it. The weaker jobs data cuts both ways, since easing rate pressure helps leveraged balance sheets but a cooling labor market can hurt consumer-facing companies that depend on household spending, such as restaurant operator The ONE Group Hospitality and travel deals publisher Travelzoo.